Early Manifest Huntington Disease
1 clinical trials · Condition
◉ Watch Early Manifest Huntington Disease
| Record | Firm | Date |
|---|---|---|
| A Dose Range Finding Study With Open-Label Extension to Evaluate the Safety of Oral LMI070/Branaplam in Early Manifest Huntington's Disease (NCT05111249) | Novartis Pharmaceuticals | 2021-12-08 |
Track Early Manifest Huntington Disease automatically
Every clearance here is in the API, with alerts when new ones post.